NICE - Endorsed Technology Appraisals 2006/2007

The following NICE Technology Appraisals were endorsed by the DoH in 2006/2007

Technology Appraisals

Fully Endorsed

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA94 - Cardiovascular Disease - Statins

  • This guidance has been updated and replaced by NICE CG181 - Lipid Modification, which was endorsed by the DoH in September 2014 HSC (SQSD) (NICE CG181) 22/14 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA101 - Prostate Cancer (hormone refractory) - Docetaxel - HSS (SQSD) (NICE) 04/07 

‚ÄčNational Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA104 - Psoriatic Arthritis - Etanercept & Infliximab

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA105 - Colorectal Cancer - Laparoscopic Surgery (review) - HSS (SQSD) (NICE) 03/07 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA107 - Breast Cancer (early) Trastuzumab (Herceptin) - HSS (SQSD) (NICE) 02/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA108 - Breast Cancer (early) - Paclitaxel - HSS (SQSD) (NICE) 06/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA109 - Breast Cancer (early) - Docetaxel - HSS (SQSD) (NICE) 05/07

Back to top